Alkermes plc. (ALKS) stock
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Alkermes plc. grew revenue 10.8% to $1.67B over the twelve months to Jun 30, 2026. Operating income fell 68.7% to $117.26M, moving the operating margin from 24.9% to 7.0%. Free cash flow was $221.65M, down 53.8% from a year earlier. At the latest close the market valued the company at $8.03B, 126.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.03B
- P/E ratio
- 126.0
- Price to sales
- 4.82
- Price to book
- 4.44
- Dividend yield
- –
- Free cash flow yield
- 2.76%
Fundamentals
- Revenue
- $1.67B
- Net income
- $66.12M
- EPS, diluted
- $0.38
- Free cash flow
- $221.65M
- Book value per share
- $10.43
- Diluted shares
- 173M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $46.47
- Open
- $46.47
- Day's range
- $46.08 – $48.00
- Volume
- 1,031,864
- Average volume (20 days)
- 1,772,471
- Beta (5 years)
- 0.42
- 52-week range
- $27.00 – $55.67
- RSI (14 days)
- 67.6
- Volatility (1 year)
- 40.5%
- Relative volume
- 0.56×
- WACC
- 6.7%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALKS | S&P 500 | Difference | ALKS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.9% | -2.4% | +20.3 pts | ||
| 3 months | -2.7% | -1.2% | −1.5 pts | ||
| Year to date | +71.2% | +12.3% | +58.9 pts | ||
| 1 year | +41.6% | +12.4% | +29.2 pts | ||
| 3 years | +101.2% | +78.8% | +22.4 pts | +26.2% | +21.4% |
| 5 years | +95.3% | +75.2% | +20.1 pts | +14.3% | +11.9% |
| 10 years | -18.2% | +311.1% | −329.3 pts | -2.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alkermes filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Alkermes
Pharmaceutical Preparations
Alkermes plc is a biopharmaceutical company focusing on treatments for neurological and psychiatric conditions. Its proprietary commercial portfolio includes Aristada and Aristada Initio for schizophrenia, Lybalvi for schizophrenia and bipolar I disorder, Vivitrol for alcohol and opioid dependence, and Lumryz for narcolepsy. Additionally, the company licenses proprietary formulations to corporate partners, including Janssen for antipsychotics and Biogen for multiple sclerosis. Its products serve adult and pediatric patients with chronic diseases, as well as certified healthcare professionals and pharmacies.
Company profile, executives and historyAlkermes stock: common questions
What is Alkermes's stock price?
ALKS closed at $47.89 on Nov 11, 2026, up 3.06% on the day. Over the past 52 weeks it traded between $27.00 and $55.67.
What is Alkermes's market cap?
Alkermes was worth $8.03B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ALKS's P/E ratio?
ALKS trades at 126.0 times earnings, based on diluted earnings per share of $0.38 over the twelve months to Jun 30, 2026.
How much revenue does Alkermes make?
Alkermes reported revenue of $1.67B for the twelve months to Jun 30, 2026, up 10.8% from a year earlier.
Does Alkermes pay a dividend?
No. Alkermes has not paid a cash dividend over the last twelve months.
When does Alkermes report earnings next?
Alkermes is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ALKS stock performed over the past year?
Including dividends, ALKS returned +41.6% over the past year, against +12.4% for the S&P 500.
How many ALKS shares are sold short?
20M shares were sold short at the latest FINRA report, 11.90% of the float, or 11.3 days of average trading volume.
Who are Alkermes's competitors?
Companies most similar to Alkermes by business, industry and size include ACAD, SUPN, AXSM, INSM, AMRX.
See a number that looks wrong?